enVVeno Medical Corp (NVNO) shareholders
Close on Nov 18, 2026Market cap $4.01MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC Joint filing with Joseph Edelman (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 2,048,515 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Mark Kingdon Joint filing with Kingdon Capital Management, L.L.C. (7.10%), M. Kingdon Offshore Master Fund, L.P. (6.60%) and 1 more | 1,359,261 | 7.10% | 13G (passive) | Sep 2, 2025 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (7.06%), Daniel Mack (7.06%) | 1,285,857 | 7.06% | 13G (passive) amendment | Sep 30, 2024 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (9.99%), Joseph Edelman (9.99%) | 68,525 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Kingdon Capital Management, L.L.C. Joint filing with M. Kingdon Offshore Master Fund, L.P. (5.50%), Kingdon GP, LLC (5.50%) and 1 more | 36,166 | 5.50% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NVNO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kingdon Capital Management, L.L.C. | 36,166 | 5.21% | $387.34K | – | 0.04% |
| CM Management, LLC | 35,714 | 5.14% | $382.50K | – | 0.25% |
| Vanguard Capital Management LLC | 6,287 | 0.90% | $67.40K | – | 0.00% |
| JPMorgan Chase & Co | 5,208 | 0.75% | $59.11K | −1 | 0.00% |
| Vanguard Fiduciary Trust Co | 2,184 | 0.31% | $23.41K | – | 0.00% |
| Westside Investment Management, Inc. | 1,525 | 0.22% | $16.33K | −64 | 0.00% |
| Mirae Asset Global Investments Co., Ltd. | 539 | 0.08% | $5.77K | New | 0.00% |
| BlackRock, Inc. | 414 | 0.06% | $4.43K | −1,426 | 0.00% |
| Tower Research Capital LLC (TRC) | 331 | 0.05% | $3.55K | −211 | 0.00% |
| Wells Fargo & Company/Mn | 114 | 0.02% | $1.22K | – | 0.00% |
| Allied Private Wealth LLC | 88 | 0.01% | $978 | New | 0.00% |
| Vanguard Global Advisers, LLC | 77 | 0.01% | $825 | – | 0.00% |
| Morgan Stanley | 59 | 0.01% | $632 | −17 | 0.00% |
| Osaic Holdings, Inc. | 7 | 0.00% | $74 | – | 0.00% |
| Group One Trading, L.P. | 2 | 0.00% | $21 | – | 0.00% |
| Barclays PLC | 2 | 0.00% | $21 | New | 0.00% |
| UBS Group AG | 1 | 0.00% | $11 | −242 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 17 | 0M | 12.8% | 3 / 0 | 6 / 3 | 0M | 0M |
| Q1 2026 | 17 | 0M | 14.5% | 17 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NVNO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 6,287 | 0.90% | $67.40K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 5,995 | 0.86% | $67.92K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 841 | 0.12% | $9.53K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 805 | 0.12% | $9.12K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 585 | 0.08% | $6.63K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Andrew Berman | Chief Executive Officer, Director | 22,236 | 3.20% | Dec 18, 2025 |
| Hamed Alavi | Chief Technology Officer | 8,334 | 1.20% | Dec 18, 2025 |
| Marc H. Glickman | SVP & Chief Medical Officer | 1,600 | 0.23% | Dec 18, 2025 |
| Jennifer Bright | Chief Financial Officer | – | – | May 20, 2025 |
| Francis Duhay | Director | 2,351 | 0.34% | Sep 14, 2026 |
| Matthew Jenusaitis | Director | 16,545 | 2.38% | Dec 15, 2025 |
| Robert Gray | Director | 11,155 | 1.61% | Dec 15, 2025 |
| Sanjay Shrivastava | Director | 9,288 | 1.34% | Dec 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Francis Duhay Director | Sep 11, 2026 | Sale(10b5-1 plan) | −11 | $11.21 | $123 | 2,351 |
| Francis Duhay Director | Jun 11, 2026 | Sale(10b5-1 plan) | −140 | $10.31 | $1.44K | 2,362 |
| Francis Duhay Director | Mar 12, 2026 | Sale(10b5-1 plan) | −140 | $11.52 | $1.61K | 2,502 |
| Francis Duhay Director | Dec 11, 2025 | Sale(10b5-1 plan) | −4,900 | $0.36 | $1.76K | 92,544 |
| Francis Duhay Director | Sep 15, 2025 | Sale(10b5-1 plan) | −4,900 | $0.83 | $4.07K | 97,444 |
| Francis Duhay Director | Dec 31, 2024 | Buy | +81,433 | $3.07 | $250.00K | 102,344 |
| Robert Gray Director | Dec 31, 2024 | Buy | +3,500 | $2.94 | $10.29K | 11,155 |
| Sanjay Shrivastava Director | Dec 24, 2024 | Buy | +5,400 | $2.90 | $15.66K | 9,288 |
| Matthew Jenusaitis Director | Dec 19, 2024 | Buy | +9,620 | $2.53 | $24.34K | 16,545 |
| Robert Andrew Berman Chief Executive Officer, Director | Dec 19, 2024 | Buy | +12,000 | $2.55 | $30.60K | 222,236 |
| Hamed Alavi Chief Technology Officer | Mar 13, 2024 | Option exercise | +8,334 | $3.59 | $29.92K | 8,334 |
| Hamed Alavi Chief Technology Officer | Mar 13, 2024 | Sale | −8,334 | $6.22 | $51.84K | 0 |
| Robert Gray Director | Sep 13, 2022 | Option exercise | +1,041 | – | – | 7,655 |
| Matthew Jenusaitis Director | Sep 13, 2022 | Option exercise | +1,041 | – | – | 6,925 |
| Francis Duhay Director | Aug 16, 2022 | Buy | +7,751 | $6.14 | $47.59K | 20,911 |
| Sanjay Shrivastava Director | Jun 30, 2022 | Buy | +1,000 | $3.85 | $3.85K | 3,888 |
| Robert Andrew Berman Chief Executive Officer, Director | Jun 27, 2022 | Buy | +2,500 | $3.80 | $9.50K | 210,236 |
| Robert Andrew Berman Chief Executive Officer, Director | Nov 30, 2021 | Award | +200,000 | – | – | 207,736 |
| Craig Glynn Chief Financial Officer | Nov 30, 2021 | Award | +50,000 | – | – | 50,000 |
| Marc H. Glickman SVP & Chief Medical Officer | Nov 30, 2021 | Award | +100,000 | – | – | 101,600 |
| Robert Andrew Berman CEO, Director | Nov 19, 2021 | Buy | +2,000 | $7.43 | $14.86K | 7,736 |
| Robert Andrew Berman CEO | Nov 16, 2021 | Buy | +2,000 | $7.87 | $15.74K | 5,736 |
| Sanjay Shrivastava Director | Nov 16, 2021 | Option exercise | +388 | – | – | 2,888 |
| Robert Gray Director | Sep 13, 2021 | Option exercise | +1,042 | – | – | 6,614 |
| Matthew Jenusaitis Director | Sep 13, 2021 | Option exercise | +1,042 | – | – | 5,884 |
| Matthew Jenusaitis Director | Aug 25, 2021 | Buy | +1,300 | $7.70 | $10.01K | 4,842 |
| Robert Gray Director | Jun 16, 2021 | Buy | +2,000 | $6.25 | $12.50K | 5,572 |
| Marc H. Glickman SVP & Chief Medical Officer | May 21, 2021 | Buy | +1,600 | $5.90 | $9.44K | 1,600 |
| Robert Andrew Berman Chief Executive Officer, Director | May 18, 2021 | Buy | +3,000 | $5.47 | $16.41K | 3,736 |
| Francis Duhay Director | May 17, 2021 | Buy | +9,492 | $5.33 | $50.59K | 13,160 |
| Biodyne Holding, S.A. – | Aug 21, 2020 | Sale | −75,000 | $0.38 | $28.50K | 1,405,433 |
| Biodyne Holding, S.A. – | Aug 20, 2020 | Sale | −75,000 | $0.27 | $20.25K | 1,480,433 |
| Biodyne Holding, S.A. – | Aug 19, 2020 | Sale | −50,000 | $0.30 | $15.00K | 1,555,433 |
| Biodyne Holding, S.A. – | Aug 18, 2020 | Sale | −50,000 | $0.34 | $17.00K | 1,605,433 |
| Biodyne Holding, S.A. – | Aug 14, 2020 | Sale | −50,000 | $0.31 | $15.50K | 1,655,433 |
| Biodyne Holding, S.A. – | Aug 3, 2020 | Sale | −70,000 | $0.32 | $22.40K | 1,705,433 |
| Biodyne Holding, S.A. – | Jul 31, 2020 | Sale | −5,000 | $0.34 | $1.70K | 1,775,433 |
| Biodyne Holding, S.A. – | Jul 30, 2020 | Sale | −25,000 | $0.32 | $8.00K | 1,780,433 |
| Biodyne Holding, S.A. – | Jul 21, 2020 | Sale | −50,000 | $0.45 | $22.50K | 1,805,433 |
| Biodyne Holding, S.A. – | Jul 20, 2020 | Sale | −150,000 | $0.43 | $64.50K | 1,855,433 |
| Matthew Jenusaitis Director | Jul 18, 2020 | Award | +62,500 | – | – | 62,500 |
| Robert Gray Director | Jul 18, 2020 | Award | +62,500 | – | – | 78,250 |
| Sanjay Shrivastava Director | Jul 18, 2020 | Award | +62,500 | – | – | 97,500 |
| Francis Duhay Director | Jul 18, 2020 | Award | +62,500 | – | – | 107,228 |
| Biodyne Holding, S.A. – | Jul 17, 2020 | Sale | −50,000 | $0.38 | $19.00K | 2,005,433 |
| Biodyne Holding, S.A. – | Jul 16, 2020 | Sale | −50,000 | $0.38 | $19.00K | 2,055,433 |
| Biodyne Holding, S.A. – | Jul 6, 2020 | Sale | −6,450 | $0.39 | $2.52K | 2,105,433 |
| Biodyne Holding, S.A. – | Jul 2, 2020 | Sale | −57,000 | $0.40 | $22.80K | 2,111,883 |
| Biodyne Holding, S.A. – | Jul 1, 2020 | Sale | −45,000 | $0.38 | $17.10K | 2,168,883 |
| Biodyne Holding, S.A. – | Jun 29, 2020 | Sale | −68,094 | $0.39 | $26.56K | 2,213,883 |
| Biodyne Holding, S.A. – | Jun 26, 2020 | Sale | −80,000 | $0.38 | $30.40K | 2,281,977 |
| Biodyne Holding, S.A. – | Jun 25, 2020 | Sale | −100,000 | $0.40 | $40.00K | 2,361,977 |
| Biodyne Holding, S.A. – | Jun 24, 2020 | Sale | −55,530 | $0.42 | $23.32K | 2,461,977 |
| Biodyne Holding, S.A. – | Jun 23, 2020 | Sale | −80,000 | $0.43 | $34.40K | 2,517,507 |
| Biodyne Holding, S.A. – | Jun 22, 2020 | Sale | −63,186 | $0.46 | $29.07K | 2,597,507 |
| Biodyne Holding, S.A. – | Jun 19, 2020 | Sale | −80,000 | $0.46 | $36.80K | 2,660,693 |
| Biodyne Holding, S.A. – | Jun 18, 2020 | Sale | −61,640 | $0.45 | $27.74K | 2,740,693 |
| Biodyne Holding, S.A. – | Jun 17, 2020 | Sale | −203,100 | $0.48 | $97.49K | 2,802,333 |
| Biodyne Holding, S.A. – | Jun 16, 2020 | Sale | −150,000 | $0.43 | $64.50K | 3,005,433 |
| Biodyne Holding, S.A. – | Jun 15, 2020 | Sale | −100,000 | $0.42 | $42.00K | 3,155,433 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of enVVeno Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 46 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Francis Duhay Director | Sep 11, 2026 | 11 | $123 | Sep 11, 2026 | OPEN MARKET PURCHASE |
| Francis Duhay Director | Jun 11, 2026 | 140 | $1.44K | Jun 11, 2026 | OPEN MARKET PURCHASE |
| Francis Duhay Director | Mar 12, 2026 | 140 | $1.61K | Mar 12, 2026 | OPEN MARKET PURCHASE |
| Francis Duhay Director | Sep 15, 2025 | 9,800 | $8.14K | Sep 15, 2025 | OPEN MARKET PURCHASE |
See a number that looks wrong?